Table 2.
Clinical characteristics after propensity score matching (n = 42).
| Clinical Characteristics | HIV (n = 21) | Non-HIV (n = 21) | p Value | |
|---|---|---|---|---|
| Age | Mean (SD) | 51.05 (10.40) | 51.43 (10.16) | 0.91 |
| <50 | 10 (47.62%) | 10 (47.62%) | ||
| ≥50 | 11 (52.38%) | 11 (52.38%) | 1.00 | |
| Menopause | no | 9 (42.86%) | 10 (47.62%) | |
| yes | 12 (57.14%) | 11 (52.38%) | 0.76 | |
| Hormone receptor | positive | 12 (57.14%) | 12 (57.14%) | |
| negative | 9 (42.86%) | 9 (42.86%) | 1.00 | |
| Her-2 | positive | 9 (42.86%) | 7 (33.33%) | |
| negative | 12 (57.14%) | 14 (66.67%) | 0.53 | |
| Tumor size (cm) | Mean (SD) | 4.40 (2.47) | 2.80 (1.35) | 0.01 |
| t > 5 cm | 3 (14.29%) | 2 (9.52%) | ||
| 5 ≥ t > 2cm | 13 (61.90%) | 10 (47.62%) | ||
| t ≤ 2 cm | 5 (23.81%) | 9 (42.86%) | 0.55 | |
| Lymph node involvement | no | 8 (38.10%) | 11 (52.38%) | |
| yes | 13 (61.90%) | 10 (47.62%) | 0.35 | |
| Molecular type | Luminal A | 1 (4.76%) | 1 (4.76%) | |
| Luminal B | 11 (52.38%) | 11 (52.38%) | ||
| HER-2 | 5 (23.81%) | 5 (23.81%) | ||
| TNBC | 4 (19.05%) | 4 (19.05%) | 1.00 | |
| Stage | 0 | 1 (4.76%) | 1 (4.76%) | |
| I | 2 (9.52%) | 5 (23.81%) | ||
| II | 11 (52.38%) | 9 (42.86%) | ||
| III | 5 (23.81%) | 6 (28.57%) | ||
| IV | 2 (9.52%) | 0 (0%) | 0.56 |